Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 259-715-3 | CAS number: 55589-62-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1974
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Scientifically reliable study with sufficient information for evaluation and assessment
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 974
- Report date:
- 1974
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Deviations:
- yes
- Remarks:
- fewer parameters in clinical pathology, gross pathology, histopathology, no ophthalmology
- GLP compliance:
- no
- Remarks:
- Study performed prior to implementation of GLP
- Limit test:
- no
Test material
- Reference substance name:
- 6-methyl-1,2,3-oxathiazine-4(3-H)-one-2,2-dioxide potassium salt
- IUPAC Name:
- 6-methyl-1,2,3-oxathiazine-4(3-H)-one-2,2-dioxide potassium salt
- Reference substance name:
- 6-methyl-1,2,3-oxathiazin-4(3H)-one 2,2-dioxide, potassium salt
- EC Number:
- 259-715-3
- EC Name:
- 6-methyl-1,2,3-oxathiazin-4(3H)-one 2,2-dioxide, potassium salt
- Cas Number:
- 55589-62-3
- Molecular formula:
- C4H5NO4S.K
- IUPAC Name:
- potassium 6-methyl-2,2,4-trioxo-3,4-dihydro-1,2λ⁶,3-oxathiazin-3-ide
- Reference substance name:
- Acesulfame potassium
- IUPAC Name:
- Acesulfame potassium
- Test material form:
- solid: crystalline
- Details on test material:
- - Name of test material (as cited in study report): Hoe 0-95 K
- Physical state: crystalline powder
- Analytical purity:>99.8%
- Lot/batch No.: VP 528 G 511
- Stability under test conditions: stable
- Storage condition of test material: room temperature
Constituent 1
Constituent 2
Constituent 3
Test animals
- Species:
- rat
- Strain:
- other: Wistar derived
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: CIVO colony, The Netherlands
- Age at study initiation: young adult
- Housing: five per cage, scren-bottomed cages
- Diet: ad libitum (prepared laborytory diet)
- Water: ad libitum (tap water)
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 24 - 26
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- DIET PREPARATION
- Rate of preparation of diet (frequency): each fourth day
- Mixing appropriate amounts with (Type of food): prepared laboratory diet
- Storage temperature of food: room temperature - Analytical verification of doses or concentrations:
- not specified
- Details on analytical verification of doses or concentrations:
- Not applicable
- Duration of treatment / exposure:
- 90 days
- Frequency of treatment:
- daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 other: %
- Remarks:
- (0 ppm or 0 mg/kg bw)
- Dose / conc.:
- 1 other: %
- Remarks:
- (10000 ppm or 500 mg/kg bw)
- Dose / conc.:
- 3 other: %
- Remarks:
- (30000 ppm or 1500 mg/kg bw)
- Dose / conc.:
- 10 other: %
- Remarks:
- (100000 ppm or 5000 mg/kg bw)
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, plain diet
- Details on study design:
- - Dose selection rationale: Request of sponsor
- Rationale for animal assignment (if not random): Forty male and forty female weanling albino rats from the CIVO-colony (Wistar derived) were divided according to body weight into four groups of ten males and ten females each - Positive control:
- None
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily
BODY WEIGHT: Yes
- Time schedule for examinations: weekly
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes, in first 4 weeks and in weeks 11 and 12
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: No
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
- Time schedule for examinations:
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: prior to termination in week 13
- Anaesthetic used for blood collection: No
- Animals fasted: No
- How many animals: 10 per sex and group
- Parameters examined: haemoglobin content, haematocrit value, red blood cell counts and total and differentialwhite blood cell counts
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: prior to termination in week 13
- Animals fasted: No
- How many animals: 10 per sex and group
- Parameters examined: serum glutamic-pyruvic transaminase (SGPT), serum glutamic-.oxalacetic transaminase (SGOT), serum alkalinephosphatase (SAP) activity and total serum protein and albumin content
URINALYSIS: Yes
- Time schedule for collection of urine: prior to termination in week 13
- Metabolism cages used for collection of urine: No data
- Animals fasted: Yes
- Parameters examined: appearance, pH, glucose, protein, occult blood, ketones and microscopy of the sediment
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (complee)
Organ weights: heart, kidneys, liver, spleen, brain, testicles/ovaries, thymus, thyroid, adrenals and caecum (filled and empty)
HISTOPATHOLOGY: Yes
In all male and female rats of control and high dose groups
Organs/tissues: lung, salivary glands, trachea, thoracic aorta, skeletal muscle, axillary and mesenteric lymph nodes, pancreas, urinary bladder, prostate, epididymis, uterus, mammary gland, esophagus, fore- and glandular stomach, duodenum, ileum and colon - Statistics:
- Mean and standard deviation was calculated, significance levels: * p<0.05, **p<0.01, ***p<0.001
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- General behaviour was not adversely affected at any dietary level. Slight diarrhoea was observed in males of the highest dose group.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- No mortality occurred.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Body weight and body weight gain was slightly reduced during the first 3 - 4 weeks of treatment in the animals of both sexes.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- The food consumption in the 10% group was slightly reduce during the first two to three weeks and slightly increased thereafter.
- Food efficiency:
- effects observed, treatment-related
- Description (incidence and severity):
- Food efficiency in the 10% group was distinctly lower than in controls during the first two to three weeks and slightly increased once the food consumption of the three groups was corrected for the intake of the test substance and expressed as the actual intake of stock diet only, the corrected food efficiency was similar in all groups, except for a relatively low in males of the 10% group.
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- A slight increase in haemoglobin concentration was observed in males of the high dose group
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Serum enzyme activities and albumin levels were comparable in all groups. Total serum protein level was slightly decreased in females of the high dose group.
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- Urine analyses were essentially normal in all groups.
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- The relative weights of the caecum were distinctly increased at the high dose group in both sexes and at the mid dose group in females only. The weights of the liver and kidneys were slightly increased in females of the high dose group.
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Gross examination identified enlarged caeca in the 10% group in females and males without morphological differences betwee test and control rats.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not examined
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 30 000 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- organ weights and organ / body weight ratios
- Remarks on result:
- other: Increased of the relative weights of the caecum but microscopic axamination did not reveal any abnormalities that couold be attribuited to the test substance.
Target system / organ toxicity
- Critical effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- No Observed Adverse Effects Level (NOAEL) for subchronic (90 days) oral toxicity in male and female Wistar rats was 30000 ppm (corresponding to about 1500 mg/kg bw/day) under the conditions of the study. Even the highest dose level of 100000 ppm (corresponding to about 3000 mg/kg bw/day) resulted in no severe signs of toxicity. This dose level clearly exceeded the current limit dose level of 1000 mg/kg bw/day.
- Executive summary:
The subchronic oral toxicity of Acesulfame potassium was investigated in male and female Wistar rats. Each 10 males and 10 females received dose levels of 0, 1%, 35 and 10% in the diet (0, 10000, 30000 100000 ppm, corresponding to about 0, 300, 1500, 3000 mg/kg bw/day) daily during a period of 90 days. Mortality, clinical findings and behavior were examined at least once a day, while body weight, food consumption were determined at regulary intervals. At the end of the application, hematology, clinical chemistry and urinalysis were performed. After sacrifice, a complete necropsy was performed, organ weights were determined and the animals of the control and high dose groups were subjected to histopathology.
This study is assessed as appropriate and valid since it was performed comparable to an internationally accepted testing guideline with only minor deviations. Reporting, assessment and data presentation in the study report was considered as appropriate.
Body weight and body weight gain was slightly reduced during the first 3 - 4 weeks of treatment in the animals of both sexes. Food consumption/food efficiency of the highest dose was slightly reduced during the first two to three weeks and slightly increased thereafter. A slight increase in haemoglobin concentration was observed in males of the high dose group. Serum enzyme activities and albumin levels were comparable in all groups. Total serum protein level was slightly decreased in females of the high dose group. Urinalysis was not affected. The relative weights of the caecum were distinctly increased at the high dose group in both sexes and at the mid dose group in females only. The weights of the liver and kidneys were slightly increased in females of the high dose group. Gross pathology did not show significant findings, except for enlargement of the caecum at the high dose group in both sexes but histopatholgy revealed no substance-induced findings.
Conclusion:
The No Observed Adverse Effects Level (NOAEL) for subchronic (90 days) oral toxicity in male and female Wistar rats was 30000 ppm (corresponding to about 1500 mg/kg bw/day) under the conditions of the study.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.